Related Experiment Video
Updated: Aug 9, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Clinically stable treatment-experienced adults receiving tenofovir and didanosine
Antonio Di Biagio1, Andrea Beltrame, Giovanni Cenderello
1Department of Infectious Diseases, University of Genova, Genova, Italy.
Method:
Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine.
Results:
Patients treated with TDF and ddI do not have a higher risk of early immunological or virological failure.
Conclusion:
Treatment success and increase in CD4+ lymphocytes may depend, among other factors, on historical CD4+ nadir. These data agree with previous work and argue against preemptive switches for fear of side effects or immunological/virological failure away from a successful ddI-TDF combination in clinically stable drug-experienced patients.
More Related Videos
Related Concept Videos
Antiviral Nucleoside Inhibitors
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Retrovirus Life Cycles
Therapeutic Drug Monitoring: Affecting Factors
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

